Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant vemurafenib versus placebo in resected BRAF V600-mutant cutaneous melanoma
NL-OMON47343Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) comparing Placebo with Vemurafenib (2 arms). Primary endpoint: Disease-free survival. Started Sep 2014; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON47343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47343.